![]() |
Burns McClellan handles US media for the IPO of Vaccitech, the British biopharmaceutical company that owns the technology behind AstraZeneca’s COVID-19 vaccine.
Vaccitech on April 29 priced the IPO shares at $17 each, which valued the IPO at $579M. The shares trade on the NASDAQ.
Vaccitech was co-founded by University of Oxford scientists Sarah Gilbert and Adrian Hill and has received backing from Google Ventures and Gilead Sciences.
It will receive 1.4 percent of net revenues from the AstraZeneca COVID-19 vaccine, after it is sold for profit following the end of the pandemic, according to the Financial Times.
Founded in 1988 by Lisa Burns, New York-based Burns McClellan bills itself as an independent IR/financial PR firm serving the life sciences market.
It has Ryo Imai and Robeert Flamm working the Vaccitech IPO. London’s Scius Communications (Katja Stout) is working the European media.


Joele Frank handles HealthSpan Partners as it ups its $25 per share offer for Surgery Partners, which uses FTI Consulting for strategic communications counsel.
Wendy’s has turned to Collected Strategies as it rejects what it calls an inadequate, unsolicited and non-binding takeover bid from a group led by Nelson Peltz’s Trian Partners.
Collected Strategies and AdvisRy Partners will handle Kaz Resources when it goes public in a $2B deal during the first half of next year.
FGS Global handles Marvell Technology as the semiconductor giant agrees to acquire Lumentum, a Joele Frank client, in all all-stock transaction worth $115B.
Ross Lovern, who advised clients on such matters as internal and external crises, M&A, litigation, restructurings and shareholder activism as a partner at Kekst CNC, has joined Prosek Partners as a managing director on its special situations team in New York.



